摘要
目的归纳美泊利单抗的适应证。方法查阅国内外美泊利单抗的相关文献,从其作用机制和适应证方面进行总结。结果美泊利单抗是以抗白细胞介素5为靶点的生物制剂,通过降低血液中嗜酸性粒细胞的水平而治疗重度嗜酸性粒细胞性哮喘、嗜酸性肉芽肿性多血管炎、高嗜酸性粒细胞增多综合征和慢性鼻-鼻窦炎伴鼻息肉。结论美泊利单抗临床药效强,患者耐受性良好,有望成为治疗由嗜酸性粒细胞增多引起的炎性疾病的靶向制剂。
Objective To summarize the indications of mepolizumab.Methods The relevant studies of mepolizumab at home and abroad were searched and summarized from aspects of mechanism and indications of mepolizumab.Results Mepolizumab is a biological agent targeting anti-interleukin-5,which was used to treat severe eosinophilic asthma(SEA),eosinophilic granulomatosis with polyangiitis(EGPA),hypereosinophilic syndrome(HES)and chronic rhinosinusitis with nasal polyps(CRSwNP)by decreasing the level of eosinophils in the blood.Conclusion Mepolizumab has the advantages of strong clinical efficacy and good tolerance,which may be a targeted agent for the treatment of inflammatory diseases caused by eosinophilia.
作者
钟思雨
田燕
肖桂荣
徐珽
ZHONG Siyu;TIAN Yan;XIAO Guirong;XU Ting(Department of Clinical Pharmacy,West China Hospital,Sichuan University,Chengdu,Sichuan,China 610041)
出处
《中国药业》
CAS
2022年第13期128-128,I0001-I0005,共6页
China Pharmaceuticals
基金
2020年四川省科技计划项目[2020YFS0138]。
